TerSera Canada Inc, a biopharmaceutical company with a focus in oncology and urology, announced that Health Canada has approved a supplemental New Drug Submission for Zoladex LA (goserelin acetate) 10.8mg every 12 weeks for the management of estrogen receptor-positive (ER+) early breast cancer with a high risk of recurrence or advanced breast cancer in pre- and perimenopausal women. While the monthly dose of Zoladex (3.6mg) has been approved for use in breast cancer since 1995, this recent approval provides a 3-month dosing option for young women with hormone-positive (HR+) breast cancer.
DEERFIELD, Ill., Nov. 9, 2021 /PRNewswire/ -- TerSera Therapeutics LLC announced today the presentation of patient-reported clinical and productivity outcomes data from their registry trial (RELAX) in patients with carcinoid syndrome diarrhea (CSD) receiving treatment with Xermelo (telotristat ethyl). The data were presented in virtual poster sessions during the North American Neuroendocrine Tumor Society's (NANETS) Multidisciplinary NET Medical Symposium on November 3-6, 2021.1
TerSera Therapeutics LLC announced today the online publication of the TELEPRO-II study in the Journal of Cancer Management and Research.1 The findings are from the largest, real-world study with Xermelo® (telotristat ethyl) and included 684 patients with carcinoid syndrome (CS).
DEERFIELD, Ill., March 5, 2021 /PRNewswire/ -- TerSera Therapeutics LLC announced today the presentation of data from their Phase 2 study of intravenous (IV) cetirizine versus IV diphenhydramine in the prevention of hypersensitivity infusion reactions in patients with breast cancer and other malignancies. The data were presented in virtual poster sessions during the 38th Annual Miami Breast Cancer Conference on March 4-7, 2021.1
TerSera Therapeutics has announced the addition of cetirizine as adjunctive therapy to the Centers for Disease Control and Prevention (CDC) guidelines titled ‘Interim considerations: preparing for the potential management of anaphylaxis after Covid-19 vaccination’.